Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab versus standard chemotherapy in first-line unresectable stage IV urothelial cancer
2015-001633-24Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) and bladder cancer comparing Durvalumab monotherapy, Durvalumab plus tremelimumab and Standard-of-care chemotherapy (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Sep 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2015-001633-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001633-24.